Literature DB >> 19224763

Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas.

Sibille Everhard1, Jörg Tost, Hafida El Abdalaoui, Emmanuelle Crinière, Florence Busato, Yannick Marie, Ivo G Gut, Marc Sanson, Karima Mokhtari, Florence Laigle-Donadey, Khê Hoang-Xuan, Jean-Yves Delattre, Joëlle Thillet.   

Abstract

The O(6)-methylguanine-DNA methyltransferase gene (MGMT) is methylated in several cancers, including gliomas. However, the functional role of cysteine-phosphate-guanine (CpG) island (CGI) methylation in MGMT silencing is still controversial. The aim of this study was to investigate whether MGMT CGI methylation correlates inversely with RNA expression of MGMT in glioblastomas and to determine the CpG region whose methylation best reflects the level of expression. The methylation level of CpG sites that are potentially related to expression was investigated in 54 glioblastomas by pyrosequencing, a highly quantitative method, and analyzed with respect to their MGMT mRNA expression status. Three groups of patients were identified according to the methylation pattern of all 52 analyzed CpG sites. Overall, an 85% rate of concordance was observed between methylation and expression (p < 0.0001). When analyzing each CpG separately, six CpG sites were highly correlated with expression (p < 0.0001), and two CpG regions could be used as surrogate markers for RNA expression in 81.5% of the patients. This study indicates that there is good statistical agreement between MGMT methylation and expression, and that some CpG regions better reflect MGMT expression than do others. However, if transcriptional repression is the key mechanism in explaining the higher chemosensitivity of MGMT-methylated tumors, a substantial rate of discordance should lead clinicians to be cautious when deciding on a therapeutic strategy based on MGMT methylation status alone.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19224763      PMCID: PMC2743215          DOI: 10.1215/15228517-2009-001

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  33 in total

1.  Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene.

Authors:  G S Watts; R O Pieper; J F Costello; Y M Peng; W S Dalton; B W Futscher
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

2.  De novo quantitative bisulfite sequencing using the pyrosequencing technology.

Authors:  Jean-Michel Dupont; Jörg Tost; Hélène Jammes; Ivo Glynne Gut
Journal:  Anal Biochem       Date:  2004-10-01       Impact factor: 3.365

3.  Mutations of O6-methylguanine-DNA methyltransferase gene in esophageal cancer tissues from Northern China.

Authors:  L Wang; D Zhu; C Zhang; X Mao; G Wang; S Mitra; B F Li; X Wang; M Wu
Journal:  Int J Cancer       Date:  1997-05-29       Impact factor: 7.396

4.  Methylation hot spots in the 5' flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene.

Authors:  X C Qian; T P Brent
Journal:  Cancer Res       Date:  1997-09-01       Impact factor: 12.701

Review 5.  Understanding and manipulating O6-methylguanine-DNA methyltransferase expression.

Authors:  R O Pieper
Journal:  Pharmacol Ther       Date:  1997       Impact factor: 12.310

6.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

Authors:  M Esteller; J Garcia-Foncillas; E Andion; S N Goodman; O F Hidalgo; V Vanaclocha; S B Baylin; J G Herman
Journal:  N Engl J Med       Date:  2000-11-09       Impact factor: 91.245

7.  Methylation of CpG island transcription factor binding sites is unnecessary for aberrant silencing of the human MGMT gene.

Authors:  R O Pieper; S Patel; S A Ting; B W Futscher; J F Costello
Journal:  J Biol Chem       Date:  1996-06-07       Impact factor: 5.157

8.  Characterization of the promoter region of the human O6-methylguanine-DNA methyltransferase gene.

Authors:  L C Harris; P M Potter; K Tano; S Shiota; S Mitra; T P Brent
Journal:  Nucleic Acids Res       Date:  1991-11-25       Impact factor: 16.971

Review 9.  DNA methylation and gene silencing in cancer: which is the guilty party?

Authors:  Susan J Clark; John Melki
Journal:  Oncogene       Date:  2002-08-12       Impact factor: 9.867

10.  Methylation-related chromatin structure is associated with exclusion of transcription factors from and suppressed expression of the O-6-methylguanine DNA methyltransferase gene in human glioma cell lines.

Authors:  J F Costello; B W Futscher; R A Kroes; R O Pieper
Journal:  Mol Cell Biol       Date:  1994-10       Impact factor: 4.272

View more
  74 in total

Review 1.  Treatment considerations for MGMT-unmethylated glioblastoma.

Authors:  Jennie W Taylor; David Schiff
Journal:  Curr Neurol Neurosci Rep       Date:  2015-01       Impact factor: 5.081

2.  NFKBIA deletion in glioblastomas.

Authors:  Markus Bredel; Denise M Scholtens; Ajay K Yadav; Angel A Alvarez; Jaclyn J Renfrow; James P Chandler; Irene L Y Yu; Maria S Carro; Fangping Dai; Michael J Tagge; Roberto Ferrarese; Claudia Bredel; Heidi S Phillips; Paul J Lukac; Pierre A Robe; Astrid Weyerbrock; Hannes Vogel; Steven Dubner; Bret Mobley; Xiaolin He; Adrienne C Scheck; Branimir I Sikic; Kenneth D Aldape; Arnab Chakravarti; Griffith R Harsh
Journal:  N Engl J Med       Date:  2010-12-22       Impact factor: 91.245

Review 3.  MGMT promoter methylation in malignant gliomas.

Authors:  Markus J Riemenschneider; Monika E Hegi; Guido Reifenberger
Journal:  Target Oncol       Date:  2010-08-20       Impact factor: 4.493

4.  Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.

Authors:  Hinke F van Thuijl; Tali Mazor; Brett E Johnson; Shaun D Fouse; Koki Aihara; Chibo Hong; Annika Malmström; Martin Hallbeck; Jan J Heimans; Jenneke J Kloezeman; Marie Stenmark-Askmalm; Martine L M Lamfers; Nobuhito Saito; Hiroyuki Aburatani; Akitake Mukasa; Mitchell S Berger; Peter Söderkvist; Barry S Taylor; Annette M Molinaro; Pieter Wesseling; Jaap C Reijneveld; Susan M Chang; Bauke Ylstra; Joseph F Costello
Journal:  Acta Neuropathol       Date:  2015-02-28       Impact factor: 17.088

5.  Prognostic Molecular and Imaging Biomarkers in Primary Glioblastoma.

Authors:  Edit Bosnyák; Sharon K Michelhaugh; Neil V Klinger; David O Kamson; Geoffrey R Barger; Sandeep Mittal; Csaba Juhász
Journal:  Clin Nucl Med       Date:  2017-05       Impact factor: 7.794

6.  Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas.

Authors:  Rui-Chao Chai; Ke-Nan Zhang; Yu-Qing Liu; Fan Wu; Zheng Zhao; Kuan-Yu Wang; Tao Jiang; Yong-Zhi Wang
Journal:  CNS Neurosci Ther       Date:  2018-08-16       Impact factor: 5.243

Review 7.  Gene markers in brain tumors: what the epileptologist should know.

Authors:  Quinn Ostrom; Mark L Cohen; Annie Ondracek; Andrew Sloan; Jill Barnholtz-Sloan
Journal:  Epilepsia       Date:  2013-12       Impact factor: 5.864

8.  Posttreatment Effect of MGMT Methylation Level on Glioblastoma Survival.

Authors:  Rikke H Dahlrot; Pia Larsen; Henning B Boldt; Melissa S Kreutzfeldt; Steinbjørn Hansen; Jacob B Hjelmborg; Bjarne Winther Kristensen
Journal:  J Neuropathol Exp Neurol       Date:  2019-07-01       Impact factor: 3.685

9.  Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.

Authors:  Shadi Lalezari; Arthur P Chou; Anh Tran; Orestes E Solis; Negar Khanlou; Weidong Chen; Sichen Li; Jose A Carrillo; Reshmi Chowdhury; Julia Selfridge; Desiree E Sanchez; Ryan W Wilson; Mira Zurayk; Jonathan Lalezari; Jerry J Lou; Laurel Ormiston; Karen Ancheta; Robert Hanna; Paul Miller; David Piccioni; Benjamin M Ellingson; Colin Buchanan; Paul S Mischel; Phioanh L Nghiemphu; Richard Green; He-Jing Wang; Whitney B Pope; Linda M Liau; Robert M Elashoff; Timothy F Cloughesy; William H Yong; Albert Lai
Journal:  Neuro Oncol       Date:  2013-01-17       Impact factor: 12.300

10.  MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.

Authors:  Martin J van den Bent; Hendrikus J Dubbink; Marc Sanson; Cathleen R van der Lee-Haarloo; Monika Hegi; Judith W M Jeuken; Ahmed Ibdaih; Alba A Brandes; Martin J B Taphoorn; Marc Frenay; Denis Lacombe; Thierry Gorlia; Winand N M Dinjens; Johan M Kros
Journal:  J Clin Oncol       Date:  2009-11-09       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.